China’s NMPA Accepts sNDA for Savolitinib in Locally Advanced/Metastatic MET Exon 14+ NSCLC
China’s NMPA has accepted an sNDA for approval of savolitinib for treatment-naive locally advanced/metastatic NSCLC with MET exon 14 skipping alterations.
China’s NMPA has accepted an sNDA for approval of savolitinib for treatment-naive locally advanced/metastatic NSCLC with MET exon 14 skipping alterations.
Sarah Wilder wanted a way to give back while her husband received treatment at MD Anderson for stage IV prostate cancer. A blood drive provided…
BackgroundSMARCA4, the essential ATPase subunit of SWI/SNF chromatin remodeling complex, regulates transcription through the control of chromatin structure a…
In this discussion chaired by Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The…
Apalutamide and ADT elicited a 100% biochemical recurrence-free survival rate at 24 months in high-risk localized prostate cancer following radical prostatectomy.
An abstract is unavailable.
Circulating tumor DNA (ctDNA) holds promise as a biomarker for predicting clinical responses to therapy in solid tumors, and multiple ctDNA assays are in development.…
Here, we summarize results from an analysis comparing real-world outcomes of axicabtagene ciloleucel vs chemoimmunotherapy in patients with R/R LBCL with ≥2 previous lines of…
18F-DCFPyL PSMA-PET imaging plus multi-parametric MRI improved the detection of clinically significant prostate cancer in low- and high-risk men on active surveillance.
Christine Bestvina, MD, presents a case of a 34-year-old non-smoker diagnosed with Stage IIIA NSCLC after presenting with chest wall pain; the panel then explores…
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies,…